Category: Bio & Healthcare

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has entered into a global license-in agreement worth up to USD 744.0M (approx. KRW 1.06T) with US-based Kaigene, Inc. for two novel drug candidates targeting rare autoimmune diseases. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Phase…

Read More “[Disclosure] Celltrion (068270) – Execution of License-in Agreement for Novel Drug Candidates for Rare Autoimmune Diseases / 2025-11-04” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has issued a corrected provisional earnings release for Q3 2025 on a consolidated basis, updating revenue to KRW 1.03T (+16.67% YoY) and operating profit to KRW 301.4B (+45.13% YoY) while populating all detailed net income metrics. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s…

Read More “[Disclosure] Celltrion (068270) – Provisional Earnings Release (Consolidated Basis) (Correction) / 2025-11-04” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has entered into a joint R&D and licensing agreement with Korean biotech MUSTBIO for the development of a PD-1 x VEGF x IL-2v tri-functional fusion protein novel drug, with a total potential deal value of up to KRW 712.5B. 📊 [Key Disclosure Details & Financial…

Read More “[Disclosure] Celltrion (068270) – Execution of Joint R&D and License Agreement for PD-1 x VEGF x IL-2v Tri-functional Fusion Protein / 2025-10-31” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has entered into a joint R&D agreement with Korean biotech Portrai, Inc. for target discovery and novel antibody development utilizing spatial transcriptomics platforms, with a total deal value of up to USD 87.75M (approx. KRW 125.9B). 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s…

Read More “[Disclosure] Celltrion (068270) – Execution of Joint R&D Agreement for Spatial Transcriptomics-Based Antibody Discovery / 2025-10-29” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has disclosed its Q3 2025 consolidated provisional financial results, reporting revenue of KRW 1,660.2B (+39.86% YoY), operating profit of KRW 728.8B (+115.27% YoY), and net profit of KRW 574.5B (+117.21% YoY). 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint)…

Read More “[Disclosure] Samsung Biologics (207940) – Provisional Operating Performance (Fair Disclosure) / 2025-10-28” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has submitted an application to the European Medicines Agency (EMA) to modify the Phase 3 clinical trial plan (Part 1 & 2) for ‘CT-P55’, a biosimilar to Cosentyx, following adjustments to its regulatory strategy and patient sample size. 📊 [Key Disclosure Details & Financial Summary]…

Read More “[Disclosure] Celltrion (068270) – Application for Modification of Phase 3 Clinical Trial Plan in Europe for CT-P55 (Cosentyx Biosimilar) (Part 1 & 2) / 2025-10-27” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has announced the suspension of trading for its common stock and related stock futures/options starting October 30, 2025, until the listing change date, due to electronic registration changes and cancellations stemming from a corporate spin-off. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s…

Read More “[Disclosure] Samsung Biologics (207940) – Information Disclosure / 2025-10-23” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Following market measures applied to the underlying equity, Samsung Biologics has announced that trading of its stock futures and stock options will be suspended starting October 30, 2025. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verifying Trading Suspension Enforcement…

Read More “[Disclosure] Samsung Biologics (207940) – Information Disclosure / 2025-10-23” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has decided to dispose of 5,094 common treasury shares (approx. KRW 746.8M) to grant shares following the exercise of stock options by employees. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Treasury Share Delivery Completion and Shareholding…

Read More “[Disclosure] Celltrion (068270) – Decision on Disposal of Treasury Shares / 2025-10-22” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion reported record 3rd-quarter consolidated revenue of KRW 1.026T and an all-time quarterly high operating profit of KRW 301.0B for Q3 2025. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Confirmed Results and Q3 2025 Earnings Release Disclosure…

Read More “[Disclosure] Celltrion (068270) – Provisional Consolidated Financial Results (Fair Disclosure) / 2025-10-21” »